



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV492342251US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 10, 2005

Signature: *Michelle Chicos*

(Michelle Chicos)

Docket No.: 55729 (71526)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ichiro Hirao et al.

Application No.: 09/787,196

Confirmation No.: 6079

Filed: April 26, 2001

Art Unit: 1623

For: NOVEL NUCLEIC ACID BASE PAIR

Examiner: M. C. Henry

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed as part of a Request for Continued Examination after payment of the Issue Fee along with a Petition to Withdraw Application from Issue Pursuant to 37 CFR 1.313(c).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be


an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 55729 (71526). A duplicate copy of this paper is enclosed.

Dated: May 10, 2005

Respectfully submitted,

By   
John B. Alexander, Ph.D.  
Registration No.: 48,399  
EDWARDS & ANGELL, LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/787,196-Conf. #6079
				Filing Date	April 26, 2001
				First Named Inventor	Ichiro Hirao
				Art Unit	1623
				Examiner Name	M. C. Henry
Sheet	1	of	1	Attorney Docket Number	55729(71526)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Tor et al., "Site-Specific Enzymatic Incorporation of an Unnatural Base, N <sup>6</sup> -(6-Aminoethyl)isoguanosine, into RNA," Journal of the American Chemical Society, 115:4461-4467 (1993).		
	CB	Morales et al. "Efficient replication between non-hydrogen-bonded nucleoside shape analogs," Nature Structural Biology 5:950-954 (1998).		
	CC	Kim et al., "Oligoribonucleotides Containing 8-oxo-7,8-Dihydroguanosine and 8-oxo-7,8-Dihydro-2'-O-Methylguanosine: Synthesis and Base Pairing Properties," Bioorganic & Medicinal Chemistry Letters 8:939-944 (1998).		
	CD	Singer et al., "Effect of 3' flanking neighbors on kinetics of pairing of dCTP or dTTP opposite O <sup>6</sup> -methylguanine in a defined primed oligonucleotide when <i>Escherichia coli</i> DNA polymerase I is used," Proc. Natl. Acad. Sci. USA 86:8271-8274 (1989).		
	CE	Ishikawa et al., "Chemical synthesis of novel base pairs and their enzymatic incorporation into DNA," Nucleic Acids Symposium Series 42:125-126 (1999).		
	CF	Kikugawa et al., "Platelet Aggregation Inhibitors. 2. Inhibition of Platelet Aggregation by 5', 2-, 6-, and 8-Substituted Adenosines," Journal of Medicinal Chemistry 15:387-390 (1972).		
	CG	Robins et al., "The synthesis of 2-, 6-, and 2,6-halogens substituted 9-(2,3-tri-O-acetyl-β-D-ribofuranosyl)purines," Nucleic Acids Symposium Series 9:61-63 (1981).		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

490554